Bio4Dreams Incubator’s Crowdfunding Round Starts on CrowdFundMe

Bio4Dreams, a certified incubator of innovative early-stage startups operating in the life sciences sector, specifically pharmaceutical, biotech, medical device, and digital health innovations, has launched a capital raise on the equity crowdfunding platform CrowdFundMe.

If you want to find more details about Bio4Dreams and its latest crowdfunding campaign, download for free our companion app. the born2Invets mobile app, available for both iOS and Android devices, keeps its readers up to date with the most important business headlines.

The Equity Crowdfunding Campaign

The incubator aims to raise at least €700,000 and up to a maximum of €3 million to grow and go public within 3 years.

In addition, upon completion of the raising, CrowdFundMe will collaborate with the incubator in order to identify and fund the best Made in Italy biotech startups.

The funds raised on CrowdFundMe will be used to accelerate the expansion of Bio4Dreams within a path that includes a listing on the stock exchange during 2025. The company has already garnered the support and interest of industrial partners and financial associates for such an operation.

In detail, part of the capital raised will be used to invest in an additional 12 startups and startups/SMEs already in the company.

In addition, investments in innovation hubs (such as MIND – Milano Innovation District) with new spaces and research labs will be expanded. Finally, resources will be used to support internationalization activities, mainly focused on the United States and Eastern Europe.

Bio4Dreams plans to industrialize the innovation process

Bio4Dreams owns a diversified portfolio of 12 investee companies registering a multiplier of 6x between 2018 and 2022, whose total present value is estimated at €57,560,000 with an estimated value of Bio4Dreams shares of €8,000,000.

The goal of Bio4Dreams is to industrialize the innovation process, creating an ecosystem capable of optimizing the development path of a new venture, from idea to market. This approach makes it possible to actively follow projects from their early stages of development and grow them in an international context.

In less than 5 years of activity, Bio4Dreams has created a network that spreads across 11 locations in the country and 6 international areas. In addition, the company is among the protagonists of the MIND project – Milano Innovation District (former Expo Area), the new international citadel of innovation, in which since November 2022 it has settled with its new Headquarters.

On the team of the incubator-which boasts partners of the caliber of Janssen Cilag S.p.A.-Johnson & Johnson Group, Dompé Farmaceutici, and MSD in the context of the strategic Innovation Circle project-is Laura Iris Ferro (co-founder), among Fortune Italia’s 50 Most Powerful Women and founder of several biotechs (including Nasdaq-listed Gentium).

__

(Featured image by Mika Baumeister via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Crowdfunding buzz, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.